PMID- 25572816
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20181113
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 32
IP  - 2
DP  - 2015 Feb
TI  - Microwave ablation plus chemotherapy improved progression-free survival of 
      advanced non-small cell lung cancer compared to chemotherapy alone.
PG  - 464
LID - 10.1007/s12032-014-0464-z [doi]
AB  - The aim of the study was to determine survival benefit of the microwave ablation 
      (MWA)/chemotherapy combination compared with chemotherapy alone. Patients with 
      untreated, stage IIIB or IV NSCLC and at least one additional measurable site 
      other than the ablative site were enrolled. They were divided into 
      MWA/chemotherapy group and chemotherapy group. The primary endpoint was 
      progression-free survival (PFS); secondary endpoints included response, time to 
      local progression (TTLP), overall survival (OS), and adverse events (AEs). 
      Forty-six and twenty-eight patients were enrolled in the MWA/chemotherapy group 
      and chemotherapy group, respectively. Complete ablation was observed in 84.8 % 
      patients in the MWA/chemotherapy group. Median TTLP was 27.0 months. Objective 
      response rate and disease control rate in MWA/chemotherapy group were 21.7 and 
      76.1 %, and in the chemotherapy group were 32.1 % (p = 0.320) and 75.0 % 
      (p = 0.916), respectively. MWA/chemotherapy combination prolonged PFS 
      [MWA/chemotherapy group 10.9 (95 % CI 5.1-16.7) ms vs. chemotherapy group 4.8 
      (95 % CI 3.9-5.8) ms, p = 0.001] and tended to improve OS [MWA/chemotherapy group 
      23.9 (95 % CI 15.2-32.6) ms vs. chemotherapy group 17.3 (95 % CI 15.2-19.3) ms, 
      p = 0.140]. Multivariate analyses showed that MWA was an independent prognostic 
      factor of PFS and primary tumor size was an independent prognostic factor of OS. 
      AEs of MWA were observed in 67.4 % patients. Chemotherapy-associated AEs were 
      observed in 39.1 and 53.6 % of patients in the MWA/chemotherapy and chemotherapy 
      group, respectively. MWA/chemotherapy combination improved PFS of advanced NSCLC 
      compared to chemotherapy alone, and the combination did not increase the adverse 
      events of chemotherapy.
FAU - Wei, Zhigang
AU  - Wei Z
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China, 
      weizhigang321321@163.com.
FAU - Ye, Xin
AU  - Ye X
FAU - Yang, Xia
AU  - Yang X
FAU - Huang, Guanghui
AU  - Huang G
FAU - Li, Wenhong
AU  - Li W
FAU - Wang, Jiao
AU  - Wang J
FAU - Han, Xiaoying
AU  - Han X
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20150109
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/mortality/*therapy
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/mortality/*therapy
MH  - Male
MH  - Microwaves/*therapeutic use
MH  - Middle Aged
MH  - Proportional Hazards Models
EDAT- 2015/01/13 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/01/10 06:00
PHST- 2014/12/12 00:00 [received]
PHST- 2014/12/16 00:00 [accepted]
PHST- 2015/01/10 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.1007/s12032-014-0464-z [doi]
PST - ppublish
SO  - Med Oncol. 2015 Feb;32(2):464. doi: 10.1007/s12032-014-0464-z. Epub 2015 Jan 9.